scarlet1967 wrote:
This is from the transcript, unless Paul was “lying” they have already identified the potential partners and discussions are ongoing. Deals can shape up in various ways, Wino’s post confirmed that,I believe as he said it is too early to know what will be the potential outcome of their negotiations. He also clearly mentioned they won’t give up the program, NOT SHELVED.
Apart from the 6 NASH phase 3 companies there are several other NASH companies from preclinical to various stages of trials.
So although NASH stocks are not as hot as there were a couple of years ago the condition’s growing prevalence and comorbidities are understood better now than earlier and the search for a cure is on.
They have a solid IP in the US and Europe and last year they filed an application to extend it to Asia and Africa. The drug is safe with confirmed dosage so there should be some interest from other companies which don’t want to spend millions starting a program from scratch.
“Well, I'm not going to get into the details, but the outreach has started and the discussions are ongoing and I cannot reveal where we are. But this is serious stuff. There's a fair amount of interest at this time and we're going to go through the pro-step process step wise and we'll let you know once we have more to say.
So I think that we have already with our advisor have done a mapping of the potential pharmaceutical companies, big companies, medium size with an interest in NASH, and we know what these companies are. And I think that we'll see down the road what type of partnership we can sign with them.
Thank you, Paul. Another question here, if we don't find a partner, would we decide to proceed on our own or just give up on it?
Paul Levesque
Well, we're certainly not going to give up. We have a protocol that we've worked absolutely hard to get to where it is now, and that can actually make us enter the market first, second, or third and be extremely relevant in an area of unmet medical need. So we're just, as I said, at this time, it's premature to actually go over and speculate over what would happen. But the partnership is on the table at this time. We've got an advisory company that is helping out, the process has started, the outreach is on, and we'll actually meet these organizations, unveil the data, get them to see what we have seen, get them to actually interact with the advisers, and [indiscernible] that are supporting this. And I'm very confident that they're going to want to actually be part of it.”